FOX04-DRI (10MG)

FOXO4-DRI is a synthetic senolytic peptide designed to selectively eliminate senescent cells, potentially reducing age-related cellular damage and improving tissue function.

FOXO4-DRI is a lab-engineered variant of the FOXO4 protein, a transcription factor involved in regulating cellular aging and survival. The “DRI” stands for D-retro-inverso, meaning the peptide’s amino acid sequence is reversed and uses D-amino acids instead of the natural L-amino acids. This modification makes the peptide resistant to enzymatic degradation, allowing it to remain active in the body longer.

Mechanism of Action
Senescent cells, often called “zombie cells,” stop dividing but resist apoptosis, releasing inflammatory signals that damage surrounding tissues. Normally, FOXO4 interacts with the p53 protein in these cells to prevent apoptosis, keeping them alive. FOXO4-DRI disrupts the FOXO4-p53 interaction, allowing p53 to trigger programmed cell death specifically in senescent cells while leaving healthy cells unaffected. This selective action makes FOXO4-DRI a senolytic agent, targeting only dysfunctional aging cells.

Potential Benefits
Research, primarily in animal models, suggests that FOXO4-DRI may:
Reduce tissue inflammation and oxidative stress
Improve organ and tissue function
Enhance skin appearance and elasticity
Potentially extend lifespan and reduce age-related disease risk

These effects are linked to the removal of senescent cells, which accumulate with age and contribute to chronic inflammation and tissue dysfunction

Usage
FOXO4-DRI is typically administered via subcutaneous or intravenous injection in research settings. Animal studies and anecdotal human reports suggest cycles may be repeated 1–3 times per year, but no standardized human dosage or FDA approval exists. Reported experimental dosages range from 100–300 mcg per day, but safety and efficacy in humans remain under investigation.

Key Considerations
FOXO4-DRI is not FDA-approved and should only be used under professional supervision.
Most data come from preclinical studies, so human effects are not fully established.
Its primary focus is anti-aging and senolytic activity, not enhancement of normal cellular function.

In summary, FOXO4-DRI is a promising experimental peptide that targets senescent cells to potentially mitigate age-related cellular damage, improve tissue health, and support longevity, though human research is still limited.